KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingTax ProvisionsTax Rate
Others
Ratios

Omega Healthcare Investors (OHI) EBITDA (2016 - 2025)

Historic EBITDA for Omega Healthcare Investors (OHI) over the last 17 years, with Q4 2025 value amounting to $223.0 million.

  • Omega Healthcare Investors' EBITDA rose 2826.65% to $223.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $839.5 million, marking a year-over-year increase of 3066.42%. This contributed to the annual value of $839.5 million for FY2025, which is 3066.42% up from last year.
  • According to the latest figures from Q4 2025, Omega Healthcare Investors' EBITDA is $223.0 million, which was up 2826.65% from $249.5 million recorded in Q3 2025.
  • Omega Healthcare Investors' 5-year EBITDA high stood at $252.9 million for Q1 2022, and its period low was $91.9 million during Q4 2021.
  • Its 5-year average for EBITDA is $164.7 million, with a median of $163.2 million in 2022.
  • Per our database at Business Quant, Omega Healthcare Investors' EBITDA skyrocketed by 60977.3% in 2021 and then tumbled by 6312.1% in 2023.
  • Over the past 5 years, Omega Healthcare Investors' EBITDA (Quarter) stood at $91.9 million in 2021, then grew by 15.82% to $106.5 million in 2022, then grew by 13.87% to $121.3 million in 2023, then surged by 43.41% to $173.9 million in 2024, then increased by 28.27% to $223.0 million in 2025.
  • Its last three reported values are $223.0 million in Q4 2025, $249.5 million for Q3 2025, and $200.1 million during Q2 2025.